Key Highlights

  • Karyopharm Therapeutics filed an sNDA for Accelerated Approval of XPOVIO in combination with ruxolitinib for myelofibrosis.
  • The filing cites Phase 3 SENTRY results showing spleen Volume reduction and potential disease modification.
  • The submission includes a Priority Review request.
  • An FDA filing decision is anticipated in the final quarter of 2026.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed an sNDA for accelerated approval of XPOVIO in combination with ruxolitinib for myelofibrosis, citing Phase 3 SENTRY results that demonstrated spleen volume reduction and potential disease modification.

What Happened

The submission includes a Priority Review request, with an FDA filing decision anticipated in the final quarter of 2026.

Market Reaction

The disclosed information does not include stock price or trading data for Karyopharm Therapeutics following the sNDA filing.

Outlook

The FDA's filing decision, anticipated in the fourth quarter of 2026, along with the outcome of the Priority Review request, represents the next major disclosed milestone for XPOVIO in myelofibrosis.